• At culinary doses (fresh ginger in tea/cooking, ~50-500 mg gingerol equivalents): No noticeable acute subjective effect — operates as a background functional food. Mild warming sensation in mouth/throat (TRPV1 agonism by 6-gingerol). Improves food palatability and accompanies meals; not a stim, not a sedative.
• At supplemental doses (1-2 g standardized extract): Many users report a vague "settled stomach" feeling within 30-60 min. Mild warming throughout the GI tract during the first hour. Some report a faint pro-energy / pro-mood lift, plausibly via the GI-derived 5-HT modulation, though this isn't pharmacologically robust. Subjective discrimination from placebo at this dose is unreliable.
• At higher doses (>3 g/day): Mouth and esophagus burning, heartburn, occasional reflux. Bowel transit accelerates noticeably — not diarrhea per se but looser stools and faster transit. Sweating mildly elevated (TRPV1-mediated peripheral vasodilation contributes). Some users on >4 g/day report a metallic aftertaste.
• Acute anti-nausea effect: For users with nausea triggers (motion, post-spar dehydration, hangover, light food poisoning), 500-1000 mg fresh or extract often produces noticeable nausea relief within 20-45 min. This is the most reliable subjective experience and the basis of ginger's reputation.
• Onset: 20-60 min for anti-nausea; same window for anti-inflammatory effects to begin shifting downstream markers. Steady-state inflammation markers (CRP, hs-CRP) take 4-8 weeks of daily dosing to fully shift.

• Tolerance: None clinically documented. Anti-emetic and anti-inflammatory effects persist over chronic dosing; no receptor down-regulation has been characterized for the relevant targets at typical supplement exposures.
• Cycling: Not required. Chronic daily use is supported by GRAS status, long food-use history (thousands of years across multiple cuisines), and clinical trials running 8-12 weeks of continuous use without signs of efficacy loss.
• Subjective novelty fade: Some users report that the "settled stomach" subjective effect feels less dramatic after months of use; this is regression to baseline (reduced GI inflammation = less day-to-day perceived gut symptoms to reverse), not pharmacological tolerance.
• Reset: No reset protocol needed. If subjective benefit is unclear, a 2-week pause and re-introduction can recalibrate perception.

Synergistic with

• Turmeric / curcumin — overlapping NF-κB and COX-2 inhibition with non-identical pathways. Common combo in joint/inflammation stacks; modestly additive effect on CRP in some studies. Use 500 mg curcumin (with piperine or phytosome) + 500 mg ginger extract for a baseline anti-inflammatory pair.
• Boswellia (AKBA-standardized) — pure 5-LOX inhibitor; complements ginger's dual COX-2 + 5-LOX activity. Strong stack for joint pain and chronic inflammation, useful in osteoarthritis-leaning users.
• Omega-3 (EPA/DHA, 2-3 g/day) — reduces arachidonic acid substrate for COX/LOX pathways; ginger then has less raw material to act on, and downstream inflammation is suppressed more efficiently. The classical anti-inflammatory base layer.
• Quercetin — additive anti-inflammatory + antioxidant; useful for allergy / histamine-overlap users (which Dylan's community-data block shows in low rank).
• Magnesium glycinate — neutral pairing for night-time inflammation/recovery stack.
• Vitamin C (1-2 g/day) — additive antioxidant + Vitamin C protects gingerol's redox-active compounds in vitro; cheap insurance for athletic recovery stacks.
• Black pepper / piperine — enhances absorption of co-administered curcumin (the relevant lever here); piperine doesn't dramatically affect ginger's own absorption but the trio (ginger + curcumin + piperine) is a well-established inflammation triad.

Avoid stacking with (at supplemental doses)

• Warfarin, DOACs (apixaban, rivaroxaban, dabigatran) — additive bleeding risk via COX inhibition + intrinsic antiplatelet effect of ginger.
• Daily aspirin (any cardioprotective dose) — additive antiplatelet effect.
• Other NSAIDs (chronic) — additive bleeding + GI risk. Acute occasional NSAID use is fine; chronic stacking is risky.
• Multiple high-dose anti-inflammatory herbs simultaneously (>3 of ginger, curcumin, boswellia, fish oil, garlic) — bleeding time additivity becomes clinically relevant. For pre-surgical patients, stop the whole stack 2 weeks out.
• High-dose garlic supplements (>3 g/day raw equivalent) — additive antiplatelet effect; mostly a concern in the same scenarios as the anticoagulant warning.

Neutral / safe co-administration

• Caffeine, creatine, protein/BCAA — no interactions.
• All other typical V4/V5 stack members in this archetype (citicoline, alpha-GPC, rhodiola, theanine, magnesium, NAC, D3/K2, vitamin C, beta-alanine) — neutral.
• Modafinil, bromantane, semax, selank, BPC-157, TB-500 — no known interactions.

• Warfarin (and DOACs): Most clinically relevant interaction. Ginger inhibits platelet aggregation and may potentiate anticoagulant effect. Effect at culinary doses is negligible; at supplemental doses (>2 g/day) can elevate INR with warfarin. Multiple case reports of elevated INR and bleeding events. Monitor INR if adding supplemental ginger to warfarin regimen, or avoid supplemental dosing.
• Antiplatelet agents (aspirin, clopidogrel, ticagrelor): Additive antiplatelet effect; meaningful at supplemental doses. Avoid combining without physician oversight.
• NSAIDs (ibuprofen, naproxen, etc.): Additive GI and bleeding risk. Avoid chronic stacking; acute use is generally fine.
• Antidiabetic medications (metformin, sulfonylureas, insulin, SGLT2 inhibitors, GLP-1 agonists): Additive hypoglycemic effect at supplemental doses. Monitor fasting glucose if initiating in T2DM patients on glucose-lowering meds; consider dose adjustment.
• Antihypertensives: Theoretical additive effect (ginger modestly lowers BP in some studies); not clinically significant at typical doses.
• Cyclosporine: Animal data suggest ginger may reduce cyclosporine absorption; avoid in transplant patients.
• CYP-mediated metabolism: Ginger is a weak inhibitor of CYP2C9, CYP2C19, and CYP3A4 in vitro; clinically significant interactions are not well-documented in humans at typical doses. Most CYP interactions are theoretical and don't materialize at culinary or 1-g supplemental dose.
• Calcium channel blockers (nifedipine): Animal data suggest additive effect on platelet aggregation; clinically minor.
• Tacrolimus: Theoretical reduction in absorption; relevant only for transplant population.

• CYP2C9 polymorphism: Ginger is a weak CYP2C9 inhibitor. CYP2C9 PMs (~3-5% Caucasian, including Dylan's likely ancestry) are slow metabolizers of warfarin, NSAIDs, and several anti-diabetic drugs. Theoretically, ginger supplementation in a CYP2C9 PM on warfarin would amplify bleeding risk further. Practical takeaway: awaiting Dylan's 23andMe results, but this is unlikely to gate ginger use at culinary doses. At supplemental >2 g/day with anticoagulants, CYP2C9 PM status would tilt toward avoidance.
• CYP3A4 / CYP3A5: Ginger is a weak in vitro CYP3A4 inhibitor. Most CYP3A4 substrates are unlikely to be meaningfully affected at typical ginger doses.
• No actionable PGx for ginger response itself as of 2026 — the bioactive variability is dose-driven, not genotype-driven. PGx becomes relevant for the interaction surface (anticoagulants, anti-diabetics) rather than for ginger's primary effects.
• TRPV1 variants: Theoretically affect subjective warming/burn at higher doses; not clinically relevant for the indications.

Sourcing-difficulty rating: easy. Ginger is one of the most accessible therapeutic botanicals on the planet. No legal hurdles, no online-vendor risk, no quality concerns at the food tier. The supplement tier benefits from standardization but is not required.

Dylan-specific: Buy fresh root weekly during grocery runs (under $5/month). Stock a 60-cap bottle of 1g standardized extract for training-day use (~$15, lasts 2 months). Total monthly spend ~$5-10. The cheapest line item in any V4/V5 stack.

Baseline (before initiating supplemental dose)

• hs-CRP — primary anti-inflammatory marker; expected to drop 1-2 mg/L over 4-8 weeks of 1 g/day extract.
• TNF-α — secondary inflammation marker; movement expected per Morvaridzadeh 2020 meta.
• IL-6 — likely won't move significantly at typical doses (per the same meta), but track for completeness.
• Fasting glucose + HbA1c — relevant if pre-diabetic or in body-recomp phase; expected modest reduction.
• LDL + Triglycerides — small effect expected; track as part of routine lipid panel.
• ALT/AST — baseline liver enzymes; ginger is not hepatotoxic but routine tracking is good practice.
• Platelet aggregation / bleeding time — only relevant if on anticoagulants or pre-surgical. Standard CBC + PT/PTT/INR if on warfarin.
• Subjective nausea / GI VAS — daily 1-10 scale for nausea-prone users.
• Subjective DOMS VAS — 24/48/72h post-eccentric session ratings, useful for training-day dose-response.

During use

• Weekly: subjective nausea, DOMS, gut comfort VAS — cheap and reliable subjective tracking.
• Monthly: HR, BP — minimal change expected; track for completeness.
• Quarterly: hs-CRP — primary objective marker for the anti-inflammatory indication.
• Bi-annually: full lipid panel + HbA1c — already part of Dylan's June 2026 bloodwork cadence.
• On dose change or new med add: re-evaluate — particularly anticoagulant or anti-diabetic additions.

Post-cycle

• Not applicable — no cycling required. If a user discontinues, expect hs-CRP to drift back upward over 4-8 weeks if other anti-inflammatory factors (diet, fish oil, exercise) aren't compensating.